Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication (original) (raw)
Related papers
2013
ASTRIC ADENOCARCINOMA IS the second leading cause of cancer death worldwide. 1 Although gastric cancer rates are declining in some areas, the number of deaths is expected to increase over the coming decades due to growing and aging populations in high-incidence regions such as Latin America and eastern Asia. 2 Helicobacter pylori infects more than half of the world's adult population, and chronic infection with this bacterium is the dominant risk factor for gastric cancer, accounting for an estimated two-thirds of all cases globally. 3,4 In a randomized trial in Shandong, China, eradication of H pylori using amoxicillin and omeprazole reduced gastric cancer incidence by 39% over Author Affiliations are listed at the end of this article.
World journal of gastrointestinal oncology, 2017
To estimate Helicobacter pylori (H. pylori) recurrence rate in Latin America, a region with a significant H. pylori prevalence and gastric cancer burden. PubMed, LILACS, SciELO, Cochrane databases and abstracts from relevant meetings were reviewed. Information collected included: Participants' characteristics, recruitment strategy, diagnostic modality, treatment arms, follow-up and recurrence rates. Recurrence was calculated using 100-patients-year rates, and data were pooled using a random effects model. The I(2) statistic assessed between study heterogeneity. Meta-regression analyses evaluated for effect modifying variables. Literature search yielded 163 articles. Twelve studies involving 4848 patients from 9 countries met inclusion criteria. Four hundred and thirty-two reinfections were recorded in 5487 person-years of follow-up. Pooled analysis showed a recurrence rate of 7.9 cases per 100 person-years (95%CI: 5.3-10.5). Meta-regression revealed that neither the antibiotic s...
Cancer Causes & Control, 1994
The bacteriumHelicobacter pylori (HP) has been implicated in the etiology of precancerous lesions of the stomach and there is evidence suggesting that it may influence the efficacy of chemoprevention of gastric cancer with vitamin C. Eradication seldom has been attempted in populations from developing countries, with a high prevalence of HP frequently resistant to metronidazole. A randomized, double-blind, controlled trial to evaluate the efficacy of colloidal bismuth subcitrate (120 mg q.i.d.) and amoxycillin (500 mg q.i.d.) in eradicating HP was conducted in 220 subjects drawn from a population with a high prevalence of metronidazole-resistant HP in Tachira state, Venezuela. One month after completion of two weeks' treatment, eradication rates of 6.5 percent in the treatment group and two percent in the placebo group were estimated on the basis of HP diagnosis in biopsies, and of 13.9 percent compared with 3.9 percent on the basis of a14C-urea breath test, although the negative predictive value of the breath test was very low compared with HP diagnosis in biopsies. In the treatment group, particularly among males, a significant decrease in bacterial load was detected. Reasons for failure of treatment in high HP-prevalence areas are discussed, and it is suggested that primary prevention of HP infection may be the optimal approach to reducing levels of stomach cancer in these high-risk groups.
Acta scientific gastrointestinal disorders, 2020
Background: Helicobacter pylori (H. pylori), a highly prevalent gastrointestinal organism, infects more than 50% of the global population. It is the most common risk factor for peptic ulcer disease, cancer stomach and gastric lymphoma. Eradication therapy regimens for H. pylori are highly effective. However, bacterial resistance to antibiotics and patients nonadherence to the treatment regimens significantly increased the recurrence rates of H. pylori infection in the last few decades. Patients and Methods: We evaluated and followed up 157 patients for one year after confirmed successful eradication of H. pylori infection. We investigated the patients at 3, 6, 9 and 12 months for recurrence of H. pylori infection using urea breath and stool antigen tests. Study Aim: To assess the prevalence and possible risk factors of H. pylori recurrence in Egyptian patients after eradication therapy. Results and Conclusion: We found a one-year recurrence rate of 19% after successful eradication therapy of H. pylori. The education level of the patients and alcohol consumption were the most significant predictors of H. pylori recurrence. The one-year recurrence rate in our study is high but comparable to those reported in the developing countries most probably due to high rates of re-infection
PLOS ONE, 2020
Background and aims Patients that have failed therapy for Helicobacter pylori (H. pylori) infection are incompletely characterized. The aim of this study was to characterize a H. pylori treatment resistant cohort compared to the cohorts of newly diagnosed, earlier eradicated and non-infected. Material and methods Patients were selected from routine referrals to the Endoscopy units at three different Norwegian hospitals. In all four cohorts, gastric biopsies were scored according to the Sydney classification, and symptoms according to the Gastrointestinal Symptom Rating Scale score, including sub-scores for upper gastrointestinal symptoms and functional bowel symptoms. Patients in the H. pylori resistant group were treated with a triple therapy regimen that consisted of levofloxacin, amoxicillin and a proton pump inhibitor. Results We included 185 patients, 42 H. pylori treatment resistant, 50 newly diagnosed, 61 previously H. pylori eradicated and 32 never infected. The treatment-resistant cohort had higher scores for upper gastrointestinal symptoms and functional bowel symptoms compared to the other groups except for the group being never H. pylori infected. The H. pylori resistant patients had lower Sydney scores than patients with newly diagnosed H. pylori infection. The triple combination showed a high efficacy of 91% to eradicate H. pylori. Conclusions Patients with treatment-resistant H. pylori infection had more gastrointestinal symptoms, but a lower Sydney score than patients with newly diagnosed infection. A treatment regimen
Revista Española de Enfermedades Digestivas
Background: After eradication treatment for Helicobacter pylori (H. pylori), infection could recur due to recrudescence or re-infection. The objective of this study was to determine the recurrence of H. pylori infection and identify virulent H. pylori strains one year after eradication with standard triple therapy. Material and methods: A quasi-experimental study was performed that included a patient population with digestive diseases associated with H. pylori who had received standard triple therapy. Cultures and polymerase chain reaction (PCR) was performed on gastric biopsies for strain identification in all patients prior to eradication treatment and those with a positive carbon-14 breath test one year after eradication treatment. Statistical analysis was performed using the Student's t-test and Fisher's exact test; statistical significance was set at 0.05. Results: One hundred and twenty-eight patients were studied, 51 (39.8%) were male and 77 (60.2%) were female with an average age of 54.8 years (DE 13.8). There was an annual recurrence of H. pylori infection in 12 (9.3%) patients. An annual re-infection and recrudescence occurred in nine (7%) and three (2.3%) patients respectively. The recrudescence rate for antigenic protein (cagA) was 1/30 (3.3%) patients and 2/112 (1.8%) patients for vacuolating cytotoxin (vacA). The re-infection rate for cagA was 3/30 (10%) patients and 6/112 (5.3%) patients for vacA. Conclusions: The recurrence of infection in this study was higher than that recorded in developed countries with a low prevalence of H. pylori and lower than that recorded in developing countries with a higher prevalence of H. pylori. The cagA or vacA s2/m2 strains were isolated after re-infection and recrudescence.
Low Helicobacter pylori eradication rates with 4‐and 7‐day regimens in an Iranian population
Journal of gastroenterology and hepatology, 2002
Background: In Iran, there is insufficient information on the efficacy of Helicobacter pylori eradication regimens shorter than 10 days. This study aims at assessing the efficacy of 4-and 7-day H. pylori eradication regimens in a high-incidence area of gastric cancer in Iran. Methods: Subjects with an endoscopic diagnosis of gastritis, positive urease test, and a histological diagnosis of chronic gastritis were enrolled. Patients were randomly assigned to one of three groups: AOC7 (1000 mg amoxicillin, 20 mg omeprazole, and 500 mg ...
Helicobacter Pylori Eradication: Survey conducted by the Colombian Association of Gastroenterology
2015
The aim of this study is to present the results of an online survey about strategies and schemes used by mem- bers of the Colombian Association of Gastroenterology (ACG - Asociacion Colombiana de Gastroenterologia) to diagnose and eradicate Helicobacter pylori infections in light of the Maastricht IV/ Florence Consensus Report. Information was prospectively collected between December 2013 and May 2014 through a virtual questionnaire on the official website of the Colombian Association of Gastroenterology (ACG). The survey was answered by 114 physicians, of whom 60 (52%) were internists and gastroenterologists located in major cities. The results show that 61% (n = 71) of respondents adhere to the recommendations of Maastricht for the first line eradication scheme and 66% (n = 76) adhere to the consensus' recommendations for the second line scheme. Another aspect of the survey that should be highlighted is that, in contrast to the recommendations of Maastricht that monoclonal fec...